Pixuvri And Omapro Will Get Tight Reviews After Rescheduled Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Delay forced by Washington's February blizzard mean that the products won't get approved until after the March 22 ODAC panel, and Omapro seems destined to miss its PDUFA date.
You may also be interested in...
FDA Plows Out: Telecommuting Triumphs As Blizzard Puts A Hole In CDER's Roof
PDUFA user fee dates could slip by as much as five business days because of the blizzards that shut down the federal government in Washington, D.C., Feb. 8-11
ChemGenex's Omapro Faces Scaled Back Efficacy Claims After Trial Shortcomings
Briefing documents for the advisory committee, now delayed by snow, show that many enrollees lacked a confirmed Bcr-Abl T315I mutation.
Cell Therapeutics' Pixuvri Could Be Stopped By Early Trial Termination
Advisory committee will consider whether the results for the non-Hodgkin's lymphoma treatment's Phase III trial, which suffered an unplanned early halt, are sufficient.